J
The FDA issued its first approval of a CRISPR gene-editing therapy.
The US Food and Drug Administration announced the approval of two gene-based therapies for sickle cell disease, one of which uses the genome editing technology CRISPR. It’s a big milestone, but access to the therapies for now will still be very limited and expensive, the New York Times explains.
Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates.
Loading comments
Getting the conversation ready...
Most Popular
Most Popular
- Samsung’s wider Z Fold 8 feels just right
- The new Halo remake is a reminder of what Xbox used to be
- Google hit with $1 billion fine for breaking EU antitrust rules
- The right-wing boomers protesting data centers have a lot in common with the left
- The sci-fi movie that imagines AI isn’t so dystopian after all











